Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT00379717 | Unknown Phase 1

• 2 other identifiers: VUB06-001TomoCT
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This non-randomized Phase I/II study is designed to determine the maximum tolerated dose (MTD) of thoracic radiotherapy and concurrent chemotherapy with cisplatin and docetaxel in patients with LA-NSCLC. All patients will receive weekly administrations of docetaxel 20 mg/m² and cisplatin 20 mg/m2 concurrently with radiotherapy. Radiotherapy will be delivered using helical tomotherapy in 30 daily fractions over six weeks. Patients should have recovered fully from induction concurrent chemoradiotherapy before they continue with the consolidation chemotherapy phase. Patients will be entered in cohorts of at least 5 subjects. The first cohort of patients will receive 30 fractions of 2Gy in six weeks up to a total dose of 60Gy. The concurrent chemotherapy starts at day 1 of the radiotherapy and will be administered 2-4 hours before the radiotherapy. The radiotherapy fraction size will be escalated to 2.36Gy in three steps.

Conditions

Non-Small-Cell Lung Carcinoma

Keywords

helical tomotherapy; dose escalation; chemotherapy

Outcome Measures

Primary Outcomes (1)

• To evaluate the feasibility and toxicity of radiation dose escalation using helical tomotherapy concurrently with chemotherapy (docetaxel-cisplatin combination) in stage III locally advanced non small cell lung cancer (LA-NSCLC).

Secondary Outcomes (1)

• To estimate efficacy parameters in terms of overall response rate, progression free survival and overall survival. To monitor quality of life (QOL) before, during and after treatment.

Interventions

Cisplatinum DRUG

Docetaxel DRUG

Tomotherapy DEVICE

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Informed consent is required.
• Histologically or cytologically confirmed NSCLC (adenocarcinoma, squamous cell carcinoma, large cell carcinoma or a combination of these)
• Patients must have a stage III unresectable LA-NSCLC:
• Males or females aged between 18 and 75 years.
• Life expectancy of at least 12 weeks.
• ECOG performance status 0,1 or2.
• Weight loss ≤ 10% within the last 3 months.
• Laboratory requirements at entry:
• Blood cell counts: i. Absolute neutrophils ≥ 2.0 x 109/L ii. Platelets ≥ 100 x 109/L iii. Haemoglobin ≥ 11 g/dl
• Renal function: i. Serum creatinine \< 1 x the upper limit of normal (UNL). ii. In case of borderline value of serum creatinine, the 24h creatinine clearance should be \> 60 ml/min.
• Hepatic function: i. Serum bilirubin \< 1 x UNL ii. ASAT and ALAT \< 2.5 x UNL iii. alkaline phosphatase \< 5 x UNL iv. Patient with ASAT and/or ALAT \> 1.5 x UNL associated with alkaline phosphatase\> 2.5 x UNL is not eligible for the study.
• Lung function tests at entry:
• FEV1: ≥ 50 % x Normal value
• DLCO: ≥ 50 % x Normal value
• Adequate cardiac function.

You may not qualify if:

• Diagnosis of small cell lung cancer.
• Stage IIIB NSCLC, based on the presence of malignant pleural or pericardial effusion.
• Pregnant or lactating women.
• Patients (male or female) with reproductive potential not implementing adequate contraceptive measures.
• Prior systemic chemotherapy, immunotherapy, or biological therapy including neoadjuvant or adjuvant treatment for NSCLC.
• Prior surgery for NSCLC, if less than 5 years from study.
• Prior radiotherapy for NSCLC.
• History of prior malignancy, except for cured non-melanoma skin cancer, curatively treated in-situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least five years.
• Symptomatic peripheral neuropathy Grade ≥ 2 except if due to trauma.
• Other serious concomitant illness or medical conditions:
• Congestive heart failure or angina pectoris except if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or arrhythmias.
• History of significant neurological or psychiatric disorders including dementia or seizures.
• Active infection requiring IV antibiotics.
• Active ulcer, unstable diabetes mellitus or other contra-indication to corticosteroid therapy.
• Superior vena cava syndrome contra-indicating hydration.

Sponsors & Collaborators

• AZ-VUB: lead
• Sanofi: collaborator

Study Sites (1)

UZ Brussel

Jette, 1090, Belgium

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Cisplatin; Docetaxel; Radiotherapy, Intensity-Modulated

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes; Radiotherapy, Conformal; Radiotherapy, Computer-Assisted; Radiotherapy; Therapeutics

Study Officials

• Samuel Bral, MD

  AZ-VUB

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Samuel Bral, MD

CONTACT

003224776415; samuel.bral@uzbrussel.be

Nicolas Fontaine, Mr

CONTACT

0032 2 477 54 61; nicolas.fontaine@uzbrussel.be

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 21, 2006
• First Posted: September 22, 2006
• Study Start: November 1, 2006
• Study Completion: April 1, 2008
• Last Updated: March 13, 2008

Record last verified: 2006-09

Locations

BE (1)